The FDA advice will hopefully provide guidance on the path forward, and once this is known any potential suitors can assess the cost of said path.
I assume takeover bids from potential suitors can be finalized and presented - whether they are acceptable to the NEU board is the next question.
This is why I think the FDA advice is pivotal and potentially a share price game changer.
We will either go it alone or get taken out.
An interesting time ahead leading into Christmas
The FDA advice will hopefully provide guidance on the path...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.30 |
Change
0.760(4.59%) |
Mkt cap ! $2.211B | |||
| Open | High | Low | Value | Volume |
| $17.35 | $17.94 | $17.25 | $17.64M | 1.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2533 | $17.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.45 | 1254 | 1 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |